Peer-reviewed veterinary case report
Effectiveness of RevolutionPlus vs Bravecto for ticks on cats
By Vatta, Adriano F et al.·Published in Veterinary parasitology·2019·Zoetis, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Comparative efficacy of topical treatments with RevolutionPlus (selamectin and sarolaner) and Bravectofor Cats (fluralaner) against Ixodes scapularis ticks on cats.
- Species:
- cat
Plain-English summary
A group of cats was treated for tick infestations using two different topical products: RevolutionPlus and Bravectofor Cats. RevolutionPlus, which combines selamectin and sarolaner, was applied monthly and showed over 99% effectiveness against ticks for 30 days after each treatment. In contrast, Bravectofor Cats, which contains fluralaner, was given as a single treatment and maintained over 99% effectiveness for up to 70 days. Both treatments were well-tolerated with no adverse reactions noted. Pet owners can feel confident using either product to protect their cats from ticks.
People also search for: cat tick treatment · RevolutionPlus for cats · Bravectofor Cats effectiveness
Abstract
The efficacy of three consecutive monthly treatments with a novel topical product (RevolutionPlus/StrongholdPlus, Zoetis) containing selamectin in combination with the isoxazoline, sarolaner, was compared with that of another topical isoxazoline, fluralaner [Bravecto(fluralaner topical solution) for Cats, Merck] against Ixodes scapularis ticks on cats. Twenty-four cats were ranked by pre-treatment tick counts to form groups of three and were randomly allocated to be treated with placebo, the minimum label dosage of RevolutionPlus (6 mg/kg selamectin plus 1 mg/kg sarolaner) or the minimum label dosage of Bravectofor Cats (40 mg/kg fluralaner) within the groups. On Days 0, 30, and 60, each cat in the placebo and RevolutionPlus-treated groups was treated topically, whereas cats in the Bravectofor Cats-treated group were treated topically once on Day 0 with fluralaner and, subsequently, these animals were treated with the placebo on Days 30 and 60 to maintain masking. Doses were calculated based on weight to provide the minimum label dosage for each product; the calculated volume of product to be administered was rounded off to the nearest 0.1 mL. The selamectin plus sarolaner-treated cats received effective dosages of 5.29-7.12 mg/kg selamectin and 0.88-1.19 mg/kg sarolaner, while the fluralaner cats received dosages of 35.21-43.16 mg/kg fluralaner. Cats were infested with approximately 50 unfed viable adult I. scapularis ticks on Days 5, 12, 26, 40, 54, 68, 82, and 88. Efficacy was assessed at 48 h after each infestation. There were no adverse reactions to any treatment during the study. The placebo-treated cats maintained adequate tick infestations throughout the study. Three monthly treatments with selamectin plus sarolaner (RevolutionPlus) resulted in high and consistent efficacy against I. scapularis for up to 30 days after each treatment. Based on geometric means, efficacy was ≥99.1% at all time points assessed. Treatment with fluralaner (Bravectofor Cats) provided high and consistent efficacy of ≥99.3% up to Day 70. On Day 84, efficacy was 90.1%; however, cats from which ticks were recovered on Day 84 had received approximately 4%-12% less than the minimum dosage of 40 mg/kg fluralaner. Three consecutive monthly treatments with RevolutionPlus or a single treatment with Bravectofor Cats provided >90% control of I. scapularis ticks over a 12-week time period.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/31182302/